Last updated on January 2019

A Phase 3 Study With P2B001 in Subjects With Early Parkinson's


Brief description of study

A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.

Detailed Study Description

A total of 525 eligible subjects with early untreated Parkinson's disease (PD), will be randomized to 4 treatment groups. Each subject will participate in the study for approximately 18 weeks including a 30 day screening period, 12 week treatment period, and 2 weeks follow-up period.

Clinical Study Identifier: NCT03329508

Find a site near you

Start Over

P2B001/003 Site Golden Valley

Golden Valley, MN United States
  Connect »

P2B001 Study site Edison

Edison, NJ United States
  Connect »

P2B001/003 Site Winfield

Winfield, IL United States
  Connect »

P2B001 study site Cincinnati

Cincinnati, OH United States
  Connect »

P2B001/003 New York

New York, NY United States
  Connect »

P2B001/003 Site Sarasota

Sarasota, FL United States
  Connect »

P2B001/003 Site Dallas

Dallas, TX United States
  Connect »

P2B001/003 Greenville

Greenville, SC United States
  Connect »

P2B001 Study site Syracuse

Syracuse, NY United States
  Connect »

P2B001/003 Site Port Charlotte

Port Charlotte, FL United States
  Connect »

P2B001 Study Vernon

Vernon, CT United States
  Connect »

P2B001/003 Site Scottsdale

Scottsdale, AZ United States
  Connect »

P2B001 site Los Angeles

Los Angeles, CA United States
  Connect »

P2B001/003 site Boca Raton

Boca Raton, FL United States
  Connect »

P2B001/003 Site Boca Raton

Boca Raton, FL United States
  Connect »

P2B001/003 site Miami

Miami, FL United States
  Connect »

P2B001/003 Site Tampa

Tampa, FL United States
  Connect »

P2B001/003 Site Augusta

Augusta, GA United States
  Connect »

P2B001/003 site Chicago

Chicago, IL United States
  Connect »

P2B001/003 site Kansas City

Kansas City, KS United States
  Connect »

P2B001/003 Site Lexington

Lexington, KY United States
  Connect »

P2B001/003 Site East Lansing

East Lansing, MI United States
  Connect »

P2B001/003 site St. Louis

Saint Louis, MO United States
  Connect »

P2B001/003 Site Commack

Commack, NY United States
  Connect »

P2B001/003 Site Asheville

Asheville, NC United States
  Connect »

P2B001/003 Site Toledo

Toledo, OH United States
  Connect »

P2B001/003 site Bedford

Bedford, TX United States
  Connect »

P2B001 Study site Englewood,

Englewood, CO United States
  Connect »

P2B001/003 Site Kirkland

Kirkland, WA United States
  Connect »

P2B001/003 Study site Williamsville

Williamsville, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.